ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial

Recruiting now · Not applicable

Conditions studied: Endometrial Cancer

In brief

RESILIENCE is 24-week randomized controlled trial that assesses the efficacy of a digital wellness platform, combined with online support from healthcare professionals, to enhance waist circumference and other vital health outcomes in endometrial cancer survivors.

Key facts

Study ID

NCT06038032

Run by

University of Alberta

People needed

148

Starts

2024-03-25

Expected to finish

2028-03-01

Last updated by the study team

2025-11-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• ≥ 18 years old
• Histologically confirmed endometrioid adenocarcinoma (low-grade), FIGO 2009 stages I to III.
• 1 month to 10 years post-surgery and completion of adjuvant treatment.
• BMI ≥25 and ≤45 kg/m2.
• Willing and able to adhere to the study interventions and assessments
• Seeking best weight using the readiness to change questionnaire.
• Have a cell phone compatible with the Fitbit app with internet access and Bluetooth capabilities.
• Able to speak, read and understand English.

You may not qualify if…

• Recurrent (local, regional, or distant) or metastatic EC.
• Abnormal (i.e., mutated) p53 status in combination with FIGO 2009 stage III or IV
• Weight fluctuations (±5 kg) within the previous 3 months.
• Planned surgery in the next 6 months.
• Previous bariatric surgery.
• Uncontrolled thyroid disorder
• Type 1 diabetes.
• Type 2 diabetes with HbA1c > 10% or are taking insulin, sulfonylureas, or GLP-1 agonists.
• Taking corticosteroids.
• Taking anti-obesity drugs.
• Current smoker (of any type, e.g e-cigarettes, tobacco, marihuana, vaping)
• Self-report >90 moderate-intensity min/week of aerobic physical activity on average over the past three months.
• Potential safety risk with exercise or maximal exercise testing screened with the 2023 Physical Activity Readiness Questionnaire (PAR-Q+)53, signs and symptoms of CVD, and any of the American Heart Association's absolute or relative contraindications to exercise testing.
• Physical or mobility limitations impacting ability to perform physical activity.
• Self-report following a structured hypocaloric diet (e.g., using formulated meal replacements, weight loss meal program) or a restrictive diet (intermittent fasting, or high-fat diet) in the past three months, or self-report currently following a vegan diet but for less than two years.
• Self-reported history of an eating disorder diagnosed by a physician.
• Intending to be away longer than 2 weeks consecutively during the intervention and unable to adhere to the study protocol during this period.
• Active substance abuse (alcohol, cannabis, illicit drugs, prescription drugs).
• Dual-energy x-ray absorptiometry (DXA) or magnetic resonance imaging (MRI) contraindications for research purposes, such as pacemakers or pregnancy
• Unable to participate in telephone and virtual intervention protocols (e.g., having a severe hearing or vision loss).
• Unable to adhere to the study protocol (i.e., unavailable to commit to scheduled group video conferencing sessions; limited access to the Internet; not willing to use platform, individuals who have been advised by a health professional not to lose weight or reduce caloric intake; cognitive impairment or dementia; etc.).
• Unable to come to study location.
• Unable to provide written informed consent.

Where it is running

• University of Alberta — Edmonton, Alberta, Canada (enrolling)
• University of Toronto — Toronto, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.